Overall, we found that the combination of E1/PAI-1 and ROBO4 was the best model to distinguish FCCM patients with mild and severe CDA; therefore, it may be helpful in the prognostication and stratification of FCCM cases in future clinical trials. The gene discussed is ROBO4; the disease is congenital dyserythropoietic anemia.